Stem Cells

Now Available:

The world’s largest human pluripotent stem cell (hPSC) bank at Coriell is now open.

The common diseases and disorders represented in the new CIRM hPSC Repository at Coriell include: Cardiomyopathies; Autism Spectrum Disorder, Cerebral Palsy, Epilepsy, Intellectual Disability; Idiopathic Pulmonary Fibrosis; Hepatitis C, Fatty Liver Disease; Age-Related Macular Degeneration, Primary Open Angle Glaucoma, Diabetic Retinopathy; and Alzheimer’s disease.

Click here to learn more about the collection.

The Power of Stem Cell Science

The promise of stem cell research lays in its application in understanding the progression of human disease, the ability to cure disease and reverse injury, and to better target therapies to optimize our health outcomes. Induced pluripotent stem (iPSC cell technology has the ability to revolutionize the way human disease is studied. Creating iPS cell lines from various rare and common disease states, as well as from various populations, will open the doors for pre-clinical research studies.

Coriell Institute’s Stem Cell Laboratory has developed standard operating procedures to expand and characterize human induced pluripotent stem cell lines submitted to the repository by researchers. This includes performance of in vitro and in vivo differentiation, quality control testing such as viability, mycoplasma screening, microsatellite-based identity matching to the parent cell line, and karyotype analysis. Coriell’s laboratory creates a distribution stock of each line on which it assesses pluripotency using a variety of cell and molecular techniques. The iPS cell lines available through the Coriell web catalog represent several disease states, including Huntington's Disease, Spinal Muscular Atrophy, Becker Muscular Dystrophy, Severe Combined Immunodeficiency, and Insulin-dependent Diabetes Mellitus. Each released iPS cell line is complemented with a complete Certificate of Analysis.

Recognized as one of the world's leading sources for research-grade iPS cell lines, Coriell has fortified that position by embarking on an ambitious initiative with the California Institute for Regenerative Medicine (CIRM), a foremost proponent of stem cell science. As part of a $10M research grant award from CIRM, Coriell launched a satellite biobank facility on the West Coast in early 2014 to store, manage and distribute biosamples from 3,000 individuals, that will then be used to create 9,000 well-characterized iPS cell lines. Coriell California processes samples from subjects enrolled at several different research and academic centers, including Stanford University and UCLA, and will oversee international distribution through the Coriell Biorepositories catalog.

In addition to the collections of human induced pluripotent stem cells, Coriell also banks mouse embryonic stem cells which were created to study transcription factors and their effects in the context of gene regulatory networks. Coriell began banking stem cells for research use in 2006, with funding from the state of New Jersey. Following the advent of new stem cell technologies, the Stem Cell Biobank at Coriell has been contracted by multiple agencies, including National Institute of General Medical Sciences, National Institute of Neurological Disorders and Stroke, National Institute of Aging, as well as academic scientists to perform in-house human induced pluripotent stem cells and mouse embryonic stem cells generation and characterization. In addition, the Stem Cell Biobank has cryopreserved hematopoietic progenitor cells and mononuclear cells from umbilical cord blood are available as custom service orders. Interested customers should email the Stem Cell Laboratory for more information.

Coriell has established a series of state-of-the-art technology platforms and rigorous analyses for identification and characterization of iPS cells and mouse embryonic stem cell (mESC) lines. All services are performed under stringent quality control procedures, and each characterized cell line is accompanied with a Certificate of Analysis upon completion.

Key Stem Cell Services at Coriell

  • Embryoid body formation and evaluation of lineage specific gene expression
  • Surface antigen testing
  • Karyotype analysis
  • Microsatellite analysis for parental cell line identity matching
  • Sterility testing
  • Assessment of viability after cryopreservation